Karyopharm Therapeutics
Amy Lovell is an accomplished professional with extensive experience in clinical operations and project management within the pharmaceutical and biotechnology industries. Currently serving as Sr. Director of Clinical Operations at Karyopharm Therapeutics Inc., Amy has held various leadership roles, including Clinical Trial Lead at KPS Life, LLC, and Director of Project Management at ICON plc. Previous positions include Associate Director roles at PRA Health Sciences and project management positions at companies such as PRA International, Octagon Research Solutions, and Covance. Amy's career began at AAIPharma Services Corp. as a Supervisor in Resource Management, following early experience as a Quality Assurance Specialist and Assistant Project Manager at Charles River Laboratories. Amy holds a Bachelor of Science degree in Biology from the University of North Carolina Wilmington.
This person is not in any offices
Karyopharm Therapeutics
13 followers
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).